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Abstract
Although NSAIDs have a well-established place for certain indications in the management of OA and RA,
they are associated with significant gastrointestinal (GI) toxicity. The risk of NSAID-related upper GI
events, such as dyspepsia or peptic ulcer and complications such as perforation or bleeding, is well
characterized. Non-selective NSAIDs increase the risk of peptic ulcer disease 5-fold, and that of
upper GI bleeding 4-fold, whereas selective cyclo-oxygenase-2 (COX) inhibitors are associated with a
significantly lower GI toxicity than non-selective agents. There is evidence that, while the incidence of
NSAID-related upper GI complications has decreased in recent years, that of lower GI complications
is increasing. Observational studies and analyses from studies, primarily designed to investigate upper
GI events, suggest that lower GI complications are relatively common in NSAID users and that COX-2
selective inhibitors are associated with a lower risk of these events. Such events have been poorly
characterized, but are associated with significant mortality; indeed, they may have even more serious
consequences than the better characterized upper GI events. There is thus a strong case for evaluating
the impact of such complications in prospective outcome studies. To facilitate such studies a new end-
point, Clinically Significant Upper or Lower GI Events, has been introduced that captures both upper and
lower GI events.
Key words: Adverse events, Cyclo-oxygenase-2 selective inhibitors, Clinically Significant Upper or Lower GI
Events, Gastrointestinal bleeding, Lower gastrointestinal complications, NSAIDs, Peptic ulcer, Upper gastro-
intestinal complications.
Introduction
NSAIDs have consistently been shown to be more effec-
tive than acetaminophen (paracetamol) in the manage-
ment of OA of hip or knee [1, 2] and their use is
endorsed in current OA management guidelines, which
review the available evidence [3, 4]. However, the use of
these agents is associated with gastrointestinal (GI)
toxicity [5], including asymptomatic mucosal damage
(erosions and ulcers), abdominal pain or dyspepsia with
or without mucosal damage, and serious complications
such as bleeding ulcers requiring hospitalization [6].
Such problems are common in NSAID-treated patients.
For example, in an endoscopic study by Geis et al. [7],
gastric or duodenal ulcers were present in 24% of
NSAID-treated individuals with OA or RA, whereas the
Food and Drug Administration Arthritis Advisory
Committee notes that symptomatic ulcers and potentially
life-threatening complications have been found in up to
4% of patients per year [5]. The potential impact of
these adverse events is highlighted by data from Spain,
which show that the mortality rate associated with NSAID
or ASA use is 5.6%, equivalent to 15.3 deaths per
100000 users [8]. To put this risk into perspective, data
from the USA in 2006 indicate that the risks of dying as a
result of a car accident or firearm injury are approximately
15 and 10 per 100000, respectively [9].
The past decade has seen major advances in the pre-
vention and management of ulcer complications, such
as a decrease in the prevalence of Helicobacter pylori
infection and improved treatment of acute ulcer bleeding
[10], and recent evidence suggests that these develop-
ments have been reflected in a change in the pattern of
NSAID-related GI complications seen in clinical practice
[11]. Thus, while the incidence of complications involving
the upper GI tract has decreased steadily during the last
decade, perforations and bleeding in the lower GI tract
have increased (Fig. 1). Such findings suggest that,
whereas attention has traditionally focused on NSAID-
related complications in the stomach or duodenum, we
need to adopt a broader perspective and consider the
1CIBERehd, Aragones Institute of Health Sciences, University of
Zaragoza, Zaragoza, Spain.
Correspondence to: Angel Lanas, Servicio de Aparato Digestivo,
Hospital Clı ´nico Universitario, c/ San Juan Bosco 15, 50009 Zaragoza,
Spain. E-mail: alanas@unizar.es
Submitted 4 November 2009; revised version accepted
29 January 2010.
! The Author(s) 2010. Published by Oxford University Press on behalf of The British Society for Rheumatology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5), which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
RHEUMATOLOGY
Rheumatology 2010;49:ii3–ii10
doi:10.1093/rheumatology/keq058potential adverse effects of NSAIDs in the GI tract as a
whole. This article reviews the adverse effects of
non-selective NSAID and cyclo-oxygenase-2 (COX-2)
selective inhibitors in the upper and lower GI tract, and
the need for a measurement that incorporates both upper
and lower GI complications as an endpoint in outcome
studies with NSAIDs.
Upper GI tract complications associated
with non-selective NSAIDs and COX-2
selective inhibitors
The risks of upper GI toxicity associated with
non-selective NSAIDs have been extensively studied.
Case-control studies and meta-analyses have shown
that the risk of upper GI complications is increased
4-fold in NSAID users, compared with non-users
[12, 13], and the risk of peptic ulcer disease is increased
5-fold [14]. The risk is highest during the first month of
treatment [relative risk (RR) 5.7; 95% CI 4.9, 6.6], and
then remains elevated afterwards [12]. Risk factors for
NSAID-related bleeding include age 560 years (and
especially >70 years) [12, 13], high-dose NSAID treat-
ment, a previous history of peptic ulcer with or without
complications, co-therapy with low-dose aspirin,
anti-coagulants or steroids and H. pylori infection [14]
(Fig. 2). NSAIDs and H. pylori have synergistic effects on
risk; in a meta-analysis of 16 studies involving 1625 NSAID
users, the odds ratio (OR) for peptic ulcer disease in
H. pylori-positive NSAID users was 61.1 (95% CI 9.98,
373), compared with H. pylori-negative non-users [14].
The risk of bleeding depends on the individual NSAID.
In a casecontrol study involving 2777 patients with con-
firmed upper GI bleeding, the highest risk of non-selective
NSAIDs was seen with ketorolac (RR, compared with
non-use of NSAIDs, 14.4; 95% CI 5.2, 39.9) and the
lowest with aceclofenac (RR 2.6; 95% CI 1.5, 4.6) [15],
whereas celecoxib was not associated with increased
risk of ulcer bleeding (RR 1.0; 95% CI 0.4, 2.1) [15]. The
study does not determine why this occurs, but it is quite
consistent with other casecontrol studies. It is important
to note that in many cases the first evidence of an
NSAID-related ulcer is a life-threatening complication;
for example, in a study of 235 patients with life-
threatening peptic ulcer complications, 58.2% had pre-
viously been asymptomatic [16].
Selective COX-2 inhibitors inhibit the production via
COX-2 of PGs mediating pain and inflammation, while
preserving COX-1-mediated production of PGs involved
in the maintenance of GI mucosal integrity [17, 18]. As a
result, these agents might be expected to offer a more
favourable safety profile than non-selective NSAIDs with
respect to upper GI bleeding. Although COX-1 inhibition is
not the only mechanism involved in NSAID-induced GI
toxicity, a systematic review of randomized controlled
trials has shown that COX-2 selective inhibitors produced
significantly fewer gastroduodenal ulcers (RR 0.26; 95%
CI 0.23, 0.30) and clinically important ulcer complications
(RR 0.39; 95% CI 0.31, 0.50) than non-selective NSAIDs
[19]. However, there is evidence, both from this system-
atic review and from studies such as CLASS [17] and
SUCCESS-1 [20] that this safety advantage is reduced
in patients receiving concomitant low-dose ASA treat-
ment. For example, in the SUCCESS-1 study, the risk of
ulcer complications in patients receiving naproxen or
diclofenac was significantly higher than in those receiving
the COX-2 selective inhibitor celecoxib (OR 14.1; 95% CI
1.8, 633.5; P=0.001) in the absence of ASA; in contrast,
there was no significant difference in risk between the two
groups of ASA users (OR 1.98; 95% CI 0.1, 27.4; P=0.49)
[20]. A recent meta-analysis of all available trials including
patients taking low-dose ASA combined with either
non-selective NSAIDs or COX-2 selective inhibitors, indi-
cate a 28% risk reduction (RR=0.72; 95% CI 0.62, 0.95)
of the GI risk in patients taking the combination of
ASA+COX-2 [21].
Current OA management guidelines [3, 22] recommend
that patients at increased risk of GI complications should
receive either a non-selective NSAID with an appropriate
gastroprotective agent, such as a proton pump inhibitor
(PPI), or a COX-2 selective inhibitor alone. These two stra-
tegies were compared in a randomized, double-blind trial
Fig. 1 Total number of GI complications per year (a) and estimated incidence of GI complications (per 100000
person-years) (b) in Spain, 19962005 [12]. Reproduced from Lanas et al. [11].
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fenac plus omeprazole, or celecoxib, 200mg twice daily,
for 6 months [23]. The risk of recurrent ulcer bleeding did
not differ significantly in the two groups (Fig. 3). More
recently, the same group have investigated the use of
combination therapy with a COX-2 selective inhibitor
and a PPI to prevent recurrent ulcer bleeding in high-risk
patients. In this randomized, double-blind trial, 441
patients with upper GI bleeding received celecoxib,
200mg twice daily, alone or in combination with
esomeprazole, 20mg twice daily, for 12 months [24].
The incidence of recurrent bleeding within 12 months
was significantly lower with combination therapy than
with celecoxib alone (0 vs 8.9%; P=0.0004), and there
were no differences in discontinuation rate or the inci-
dence of adverse events between the two groups.
Whereas this study was carried out in H. pylori-negative
patients, and therefore their validity in H. pylori-infected
patients can be questioned, it must be noted that patients
with ulcer history positive for H. pylori should undergo
eradication of the infection.
Lower GI tract damage associated
with NSAIDs
In contrast to the well-documented risk of upper GI
damage associated with NSAIDs, NSAID-related lower
GI damage has not been widely studied and remains
poorly characterized [25]. This damage includes increased
mucosal permeability, mucosal inflammation, overt
or occult blood loss, malabsorption, protein loss,
ileal dysfunction, diarrhoea, ulceration, strictures, major
bleeding and perforation [26]. Data on the incidence of
NSAID-related lower GI side effects come from observa-
tional or casecontrol studies, and from analyses of out-
come trials in which the primary endpoints were related to
upper GI or cardiovascular events.
Observational studies
The association between NSAIDs and injury to the lower
intestine has been recognized for almost two decades. In
a landmark study, Allison et al. [27] found post-mortem
evidence of small intestinal ulceration in 8.4% of NSAID
users, compared with 0.6% of non-users (treatment dif-
ference 7.8%; 95% CI 5.0, 10.6%; P<0.001). It must be
noted that this study probably underestimated small
bowel damage due to post-mortem autolysis [27].
Fig. 2 Risk factors for upper GI bleeding associated with NSAID use [1315]. Adapted from Pe ´rez Gutthann et al. [13],
Huang et al. [14] and Lanas et al. [15].
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Fig. 3 KaplanMeier plot showing the risk of recurrent
ulcer bleeding in 287 arthritis patients treated for 6 months
with either diclofenac, 75mg twice daily, plus omeprazole,
20mg twice daily, or celecoxib, 200mg twice daily [23].
Reproduced with permission from Chan et al. [23].
Copyright ! 2002 Massachusetts Medical Soceity.
All rights reserved.
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GI safety of NSAIDsSubsequently, three casecontrol studies showed the
association between NSAID and ASA use with both
upper and lower GI complications. One of them was a
casecontrol study involving 566 patients hospitalized
for upper or lower GI bleeding, which found that the OR
for lower GI bleeding in NSAID users, compared with
non-users, was 2.6 (95% CI 1.7, 3.9; P<0.001) [28]. The
other two used similar methodology combining objective
testing of ASA use in blood and clinical history for NSAID
use. One found that NSAID and ASA use were equally
associated with either upper or lower GI bleeding [29]
and the other one that both types of drugs were asso-
ciated with both upper and lower GI perforation [30].
Epidemiological data show that NSAID-related lower GI
complications are associated with significant mortality.
Data from an observational study in Spain showed that
the mortality rate in patients with NSAID-related lower GI
bleeding was comparable to that in patients with upper
GI bleeding (5.3 and 5.7%, respectively) [8]. Moreover,
the mortality rate among patients with either upper or
lower GI perforation was markedly higher (30.1%) than
in those with GI bleeding. More recent data from Spain
show a decrease in mortality in patients hospitalized with
upper GI events but not in the lower GI mortality rate [11].
NSAIDS can also aggravate lesions and induce GI com-
plications from pre-existing diseases such as inflamma-
tory bowel disease, diverticulosis or angiodysplasia [31].
Endoscopy studies. A number of studies have explored
the use of new technologies, such as capsule endoscopy
or double-balloon enteroscopy, to investigate the occur-
rence of mucosal lesions or events occurring along the
lower bowel. For example, two randomized, placebo-
controlled trials have used video capsule endoscopy to
assess small bowel injury in healthy volunteers treated
with either celecoxib or a combination of a non-selective
NSAID and omeprazole [32, 33]. In both studies, the inci-
dence of small bowel mucosal breaks in celecoxib-treated
participants was significantly lower than that in those
receiving the combination of a non-selective NSAID and
omeprazole, and comparable to that in the placebo group
(Fig. 4). Double-balloon enteroscopy is an invasive proce-
dure that is associated with a higher risk of surgical
complications such as perforation than conventional
endoscopy [34]. Visualization of lesions may, however,
be better. It has been reported that video capsule endo-
scopy may have a false positive rate of 43% [35], and
that this technique misses significant lesions that are
detectable by double-balloon enteroscopy [36].
Outcome clinical trials
Despite the high incidence of NSAID-related lower GI
complications in observational studies, and the mortality
associated with such complications, no published out-
come studies have specifically addressed the clinical
impact of these adverse effects on NSAID users.
Indirect evidence comes from outcome trials investigating
NSAID-related upper GI or cardiovascular complications.
The Multinational Etoricoxib and Diclofenac Arthritis
Long-term (MEDAL) study compared diclofenac and etori-
coxib in 34701 patients with OA or RA, who were treated
for up to 3.5 years, with a primary endpoint of confirmed
thrombotic cardiovascular events [37, 38]. The overall
incidence of upper and lower GI events in this study
was 0.47 and 0.56%, respectively. Upper GI events
(symptomatic ulcers plus upper GI complications) were
significantly less common with etoricoxib than with diclo-
fenac [hazard ratio (HR) 069; 95% CI 057, 083;
P=00001] [37]. In this study, 35% of patients were
receiving low-dose ASA and 39% were receiving a PPI.
These two factors may have affected the results of the
study. First, low-dose ASA combined with either etori-
coxib or diclofenac may have increased the incidence of
both upper and lower GI events. Secondly, the use of a
PPI may result in a relative increase in lower GI events
Fig. 4 Incidence of small bowel mucosal breaks, assessed by video capsule endoscopy, in two randomized,
placebo-controlled studies comparing celecoxib, 200mg twice daily, with the combination of a non-selective NSAID
and omeprazole in healthy volunteers [32, 33]. Reproduced from Goldstein et al. [32] with permission from the American
Gastroenterological Association and Goldstein et al. [33] with permission from Wiley-Blackwell.
Celecoxib, 200mg bid vs naproxen, 500mg
bid + omeprazole 20mg qd1
P=0.04
Naproxen + 
omeprazole 
(n = 111)
Celecoxib
(n = 115)
Placebo
(n = 113)
S
u
b
j
e
c
t
s
 
w
i
t
h
 
s
m
a
l
l
 
b
o
w
e
l
 
P<0.001 P<0.001
16
7
55
0
10
20
30
40
50
60
m
u
c
o
s
a
l
 
b
r
e
a
k
s
,
 
%
Celecoxib, 200mg bid vs ibuprofen, 800mg
tid + omeprazole 20mg qd2
P<0.001 P<0.001
Celecoxib 
(n = 109)
Ibuprofen
+ omeprazole
(n = 112)
Placebo
(n = 113)
6.4 
25.9 
7.1
0
5
10
15
20
25
30
P=0.776
S
u
b
j
e
c
t
s
 
w
i
t
h
 
s
m
a
l
l
 
b
o
w
e
l
 
m
u
c
o
s
a
l
 
b
r
e
a
k
s
,
 
%
ii6 www.rheumatology.oxfordjournals.org
Angel Lanaswhen compared with those of the upper GI tract. In any
case, gastroprotective therapy did not completely abolish
the risk of upper GI events. However, although this ther-
apy was supposed to be taken throughout the duration of
the trial in all patients at risk, it was not taken by the
majority of patients, and the authors suggest that it did
decrease the risk in patients who were at the greatest GI
risk and were taking PPIs.
The finding that the incidence of lower GI events in this
study was higher than that of upper GI events is not sur-
prising because, while PPIs can reduce the risk of upper
GI events they would not be expected to have a protective
effect in the mid- and large bowel. There was no signifi-
cant difference between rates of lower GI clinical events
for etoricoxib and diclofenac: rates being 0.32 and 0.38
per 100 patient-years (HR=0.84; 95% CI 0.63, 1.13),
respectively. The analysis of lower GI events did indicate
that significant risk factors for a lower GI event are a prior
lower GI event (HR=4.06; 95% CI 2.93, 5.62) and age
565 years (HR=1.98; 95% CI 1.45, 2.71) [38].
In the Misoprostol Ulcer Complications Outcomes
Safety Assessment (MUCOSA) trial with misoprostol, seri-
ous lower GI events were found by the investigators to be
more common than those from the upper GI tract and
occurred in 147 patients, whereas only 95 individuals
experienced upper GI complications [39]. Similarly, in
the Vioxx GI Outcomes Research (VIGOR) trial, which
compared naproxen and rofecoxib in 8076 patients with
RA, serious lower GI events, such as perforation, obstruc-
tion or major bleeding, accounted for 39.4% of all serious
GI adverse events among naproxen-treated patients and
42.7% of such events among rofecoxib-treated patients
[40].
The incidence of lower GI events
Together, the available evidence from epidemiological
and outcome studies indicates that NSAID-related lower
GI damage is relatively common. Only one recent study
from Canada reported lower rates of hospitalization due to
lower GI complications than upper [41]. This was a
population-based retrospective cohort study that included
644183 elderly patients, aged 565 years, who received
1778541 prescriptions for non-selective NSAIDs
(315222, 17.7% with a PPI). The study examined ulcer-
ation, perforation or bleeding in the GI tract in study
individuals taking non-selective NSAIDs or acetamino-
phen with or without a PPI. Among users of non-selective
NSAIDs without a PPI, the crude rates of hospitalization
were 0.7 cases per 1000 patient-years for lower GI
complications compared with 4.4 cases per 1000
patient-years for complications in the upper GI tract [41].
However, when the non-selective NSAID was taken with a
PPI, the rates of hospitalization were 1.4 cases per 1000
patient-years for the lower GI tract compared with 2.0
cases per 1000 patient-years for the upper GI tract [40].
It might be suggested that hospitalizations for upper but
not lower GI complications associated with non-selective
NSAIDs were reduced by the addition of a PPI.
A systematic literature review reported that mucosal
breaks or small intestinal injuries were present in up to
71% of NSAID users, and that up to 88% of patients
with lower GI bleeding were NSAID users [25]; the ORs
for bleeding or perforation associated with NSAID treat-
ment ranged from 1.9 to 18.4 or from 2.5 to 8.1, respec-
tively. The risk of such problems was lower in patients
receiving COX-2 selective inhibitors than in those receiv-
ing non-selective NSAIDs; the RRs for small mucosal
breaks, haematochezia (maroon-coloured blood in the
stool) and lower GI clinical events were 0.3 (95% CI 0.2,
0.5), 0.4 (95% CI 0.2, 0.8) and 0.5 (95% CI 0.2, 0.9;
P=0.03), respectively, compared with non-selective
agents [25].
The significance of lower GI
complications to the patient
Although serious lower GI complications such as perfora-
tion or overt bleeding are of major clinical concern
because of their life-threatening nature, events that are
less severe or even asymptomatic can still have a
marked impact on the patient. Symptomatic lesions can
lead to the patient discontinuing potentially beneficial
NSAID treatment, whereas occult blood loss or anaemia
can result in impaired physical performance and dimin-
ished quality of life. For example, in the InChianti
(Invecchiare in Chianti [Ageing in the Chianti Area])
study, the presence of anaemia (defined according to
World Health Organization criteria as a haemoglobin con-
centration <13g/dl in men or <12g/dl in women) was
associated with poorer performance (mean short physical
performance battery scores 8.8 vs 9.6; P=0.003) and
more disabilities (P<0.001), compared with non-anaemic
individuals [42]. People with anaemia also had significantly
lower knee extensor strength (14.1 vs 15.2kg; P=0.02)
and handgrip strength (25.3 vs 27.1kg; P=0.04) than
those without anaemia.
In addition to impairing performance and quality of life,
anaemia can also increase the risk of other adverse
events. Evidence for this comes from the Cardiovascular
Health Study, a prospective cohort study involving 5888
individuals aged 565 years [43]. Overall, 1205 partici-
pants were in the lowest quintile of haemoglobin concen-
tration (<13.6g/dl for men and <12.6g/dl for women),
and 498 (8.5%) were anaemic. Individuals in both the
lowest and highest quintiles of haemoglobin concentra-
tions were at significantly higher risk of both cardiovascu-
lar and overall mortality (Fig. 5), with adjusted HRs of
1.57 (95% CI 1.38, 1.78) and 1.38 (95% CI 1.19, 1.54),
respectively. These associations persisted after adjust-
ment for causes and consequences of anaemia, such as
renal dysfunction, inflammation or frailty.
The need for a new endpoint in NSAID
outcome studies
Previously, outcome studies with NSAIDs have focused
on adverse events affecting the upper GI tract, in view
www.rheumatology.oxfordjournals.org ii7
GI safety of NSAIDsof the well-established association between NSAIDs and
such complications. However, given the strong evidence
that NSAIDs also damage the lower GI tract, and that this
can have important consequences for the patient, there is
a strong case for evaluating the impact of such complica-
tions in prospective outcome studies. This will require the
use of an endpoint that captures both upper and lower
GI events.
Studies that have reported lower GI complications in
NSAID-treated patients have used a variety of endpoints,
ranging from changes in intestinal permeability resulting
from mucosal damage to overt clinical complications such
as perforation, ulceration or bleeding [25]. In general, how-
ever, the clinical endpoints of NSAID-induced damage to
the lower GI tract are not well defined, and the impact of
those that have already been described is unclear. Thus,
reliable endpoints that evaluate the entire GI tract are
needed for NSAID outcome studies.
Development ofanew endpoint: clinically significant
upper or lower GI events
It is well known that bleeding, perforation or obstruction
can occur in both the upper and the lower GI tract and can
all be associated with NSAID use [5, 6, 29]. Therefore,
evaluation of NSAID-related events in the GI tract should
include all these endpoints. Furthermore, identification of
the responsible lesion associated with a major complica-
tion is sometimes a difficult task, especially when
the responsible lesion is not identified in the upper GI
endoscopy performed soon after hospital admission.
Exploration of the small and large bowel may be difficult,
complex and require additional technology and trained
staff, which are not always available in all hospitals.
Also, delay in performing the appropriate test reduces
the probability of finding mucosal lesions induced by
NSAIDs. Consequently, major GI events not linked to a
specific lesion should not prevent the inclusion of those
events as clinical endpoints. In addition, patients using
NSAIDs may develop a significant haemoglobin drop
[25], which is not always macroscopically visualized as
GI bleeding, but that has a clear GI origin, and as noted
above, may have a relevant clinical impact. In view of
these considerations, a new endpoint has been intro-
duced that comprises both upper and lower GI events,
with or without endoscopic lesions (Table 1). This end-
point has been named Clinically Significant Upper or
Lower GI Events (CSULGIEs) [44].
This endpoint has been used in the recent Celecoxib vs
Omeprazole aNd Diclofenac for at-risk OA and RA
patients (CONDOR) study (NCT00141102), which com-
pared celecoxib, 200mg twice daily, with diclofenac
slow release (SR), 75mg twice daily, plus omeprazole,
20mg once daily [44]. The primary aim of this study was
to determine whether celecoxib is superior to combined
therapy with diclofenac SR plus omeprazole in preventing
CSULGIEs in high-risk patients with OA or RA. This study
is the first major outcome study in which lower GI events
were included in a prospectively designated endpoint. It is
expected that CONDOR will provide additional data that
may be useful for the clinician who now has two options
(COX-2 alone vs non-selective NSAIDs plus a PPI), which
are equally effective in the prevention of GI damage in the
upper GI tract. It remains to be seen whether, when con-
sidering the entire GI tract, one of the options (COX-2
alone) will be superior to the other one (ns-NSAIDs plus
a PPI) since PPIs are not expected to have any effect
beyond the duodenum.
Conclusions
The available evidence shows that the incidence of lower
GI adverse events associated with NSAID use is increas-
ing. Such events have been poorly characterized, but are
Table 1 CSULGIEs
With lesion Without lesion
Gastroduodenal haemorrhage Acute GI haemorrhage of unknown origin, including presumed
Gastric outlet obstruction small bowel haemorrhage
Gastroduodenal, small bowel or large bowel perforation Clinically significant anaemia of presumed occult GI origin,
Small bowel haemorrhage including possible small bowel blood loss
Large bowel haemorrhage
Clinically significant anaemia of defined GI origin
Fig. 5 Unadjusted mortality over 11.2 years, according
to haemoglobin concentration quintiles, in the
Cardiovascular Health Study [43]. Reproduced with per-
mission from Zakai et al. [43]. Copyright ! 2005 American
Medical Association. All rights reserved.
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Angel Lanasassociated with significant mortality; indeed, they may
have even more serious consequences than the widely
recognized and well-characterized upper GI events.
There is a clear need for new outcome measurements
that reflect the risk of lower GI events in clinical trials with
non-selective NSAIDs and COX-2 selective inhibitors. This
need has been met by the introduction of CSULGIEs as an
endpoint, which captures events occurring in the entire GI
tract. The CONDOR study, in which CSULGIEs were a
primary endpoint, is the first major outcome NSAID trial
in which lower GI adverse events were prospectively
included in primary outcome measurement. The results
of this study should demonstrate whether celecoxib is
superior to the combination of diclofenac SR and omepra-
zole in preventing CSULGIEs in high-risk patients with OA
or RA.
Rheumatology key messages
. NSAID-related lower GI complications are becom-
ing more common.
. NSAID-related lower GI complications can have a
significant impact on the patient.
. CSULGIES is a new endpoint that captures adverse
events along the entire GI tract.
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